Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD... It is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors.
- Mechanism
- Curator reviewed
GT 389-255 is a novel conjugate of a proprietary pancreatic lipase inhibitor and a fatbinding hydrogel polymer for the treatment of obesity. GT 389-255 is a novel conjugate of a proprietary pancreatic lipase inhibitor and a fat binding hydrogel polymer for the treatment of obesity. It acts within the gastro-intestinal tract to prevent fat digestion and is expected to inhibit > 30% of fat absorption. The novel conjugate is expected to have fewer side-effects than currently marketed therapies. The currently marketed pancreatic lipase inhibitor Orlistat, is associated with oily incontinence, caused by mal-absorbed triglycerides. GT 389-255 is expected to have minimal systemic exposure. Less than 1% of the lipase inhibitor is absorbed and the fat binding polymer is not absorbed.
- Primary indication
- Investigated for use/treatment in obesity.Curator reviewed
- Code names
- GT 389-255
Which companies are running trials of GT 389-255, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account